210 related articles for article (PubMed ID: 34310349)
1. Phase I Study of Docetaxel and Temsirolimus in Refractory Solid Tumors.
Amin M; Gao F; Terrero G; Picus J; Wang-Gillam A; Suresh R; Ma C; Tan B; Baggstrom M; Naughton MJ; Trull L; Belanger S; Fracasso PM; Lockhart AC
Am J Clin Oncol; 2021 Sep; 44(9):443-448. PubMed ID: 34310349
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors.
Kyriakopoulos CE; Braden AM; Kolesar JM; Eickhoff JC; Bailey HH; Heideman J; Liu G; Wisinski KB
Invest New Drugs; 2017 Jun; 35(3):290-297. PubMed ID: 28004284
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of vinblastine and temsirolimus in pediatric patients with recurrent or refractory solid tumors: Canadian Cancer Trials Group Study IND.218.
Deyell RJ; Wu B; Rassekh SR; Tu D; Samson Y; Fleming A; Bouffet E; Sun X; Powers J; Seymour L; Baruchel S; Morgenstern DA
Pediatr Blood Cancer; 2019 Mar; 66(3):e27540. PubMed ID: 30393943
[TBL] [Abstract][Full Text] [Related]
4. A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report.
Fouladi M; Perentesis JP; Wagner LM; Vinks AA; Reid JM; Ahern C; Thomas G; Mercer CA; Krueger DA; Houghton PJ; Doyle LA; Chen H; Weigel B; Blaney SM
Clin Cancer Res; 2015 Apr; 21(7):1558-65. PubMed ID: 25467181
[TBL] [Abstract][Full Text] [Related]
5. Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates.
Kelley RK; Nimeiri HS; Munster PN; Vergo MT; Huang Y; Li CM; Hwang J; Mulcahy MF; Yeh BM; Kuhn P; Luttgen MS; Grabowsky JA; Stucky-Marshall L; Korn WM; Ko AH; Bergsland EK; Benson AB; Venook AP
Ann Oncol; 2013 Jul; 24(7):1900-1907. PubMed ID: 23519998
[TBL] [Abstract][Full Text] [Related]
6. A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors.
Park H; Williams K; Trikalinos NA; Larson S; Tan B; Waqar S; Suresh R; Morgensztern D; Van Tine BA; Govindan R; Luo J; Lockhart AC; Wang-Gillam A
Cancer Chemother Pharmacol; 2021 Mar; 87(3):337-347. PubMed ID: 33159216
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.
Gandhi L; Bahleda R; Tolaney SM; Kwak EL; Cleary JM; Pandya SS; Hollebecque A; Abbas R; Ananthakrishnan R; Berkenblit A; Krygowski M; Liang Y; Turnbull KW; Shapiro GI; Soria JC
J Clin Oncol; 2014 Jan; 32(2):68-75. PubMed ID: 24323026
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer.
Chen LT; Liu TW; Wu CW; Chung TR; Shiah HS; Jan CM; Liu JM; Whang-Peng J; Chang JY
Oncology; 2002; 63(3):239-47. PubMed ID: 12381903
[TBL] [Abstract][Full Text] [Related]
9. Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer.
Bhargava P; Marshall JL; Fried K; Williams M; Lefebvre P; Dahut W; Hanfelt J; Gehan E; Figuera M; Hawkins MJ; Rizvi NA
Cancer Chemother Pharmacol; 2001 Aug; 48(2):95-103. PubMed ID: 11561784
[TBL] [Abstract][Full Text] [Related]
10. Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers.
Khawaja MR; Nick AM; Madhusudanannair V; Fu S; Hong D; McQuinn LM; Ng CS; Piha-Paul SA; Janku F; Subbiah V; Tsimberidou A; Karp D; Meric-Bernstam F; Lu KH; Naing A
Cancer Chemother Pharmacol; 2016 May; 77(5):973-7. PubMed ID: 27014780
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumors.
Semrad TJ; Eddings C; Dutia MP; Christensen S; Lara PN
Anticancer Drugs; 2013 Jul; 24(6):636-40. PubMed ID: 23698253
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors.
Spunt SL; Grupp SA; Vik TA; Santana VM; Greenblatt DJ; Clancy J; Berkenblit A; Krygowski M; Ananthakrishnan R; Boni JP; Gilbertson RJ
J Clin Oncol; 2011 Jul; 29(21):2933-40. PubMed ID: 21690471
[TBL] [Abstract][Full Text] [Related]
13. Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors.
Piatek CI; Raja GL; Ji L; Gitlitz BJ; Dorff TB; Quinn DI; Hu J; El-Khoueiry AB; Pham HQ; Roman L; Garcia AA
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1227-34. PubMed ID: 25374407
[TBL] [Abstract][Full Text] [Related]
14. [Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer].
Li JL; Zhang XR; Liu JW; Chen ZY; Lin YC; Wang YD; Chen Q; Nan KJ; Song SP; Han FC; Zhu YZ; Li LY; Zheng YH; Chu DT
Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):309-12. PubMed ID: 16875636
[TBL] [Abstract][Full Text] [Related]
15. A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041).
Chiu JW; Hotte SJ; Kollmannsberger CK; Renouf DJ; Cescon DW; Hedley D; Chow S; Moscow J; Chen Z; Perry M; Diaz-Padilla I; Tan D; Hirte H; McWhirter E; Chen H; Siu LL; Bedard PL
Invest New Drugs; 2016 Feb; 34(1):104-11. PubMed ID: 26686201
[TBL] [Abstract][Full Text] [Related]
16. A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors.
Infante JR; Cohen RB; Kim KB; Burris HA; Curt G; Emeribe U; Clemett D; Tomkinson HK; LoRusso PM
Invest New Drugs; 2017 Oct; 35(5):576-588. PubMed ID: 28424891
[TBL] [Abstract][Full Text] [Related]
17. A dose escalation study of docetaxel plus capecitabine in combination with gemcitabine in patients with advanced solid tumors.
Amarantidis K; Houhouli K; Papatheodorou K; Miloussis A; Matthaios D; Chatzaki E; Lyrantzopoulos N; Tsaroucha A; Tentes A; Kakolyris S
Oncol Res; 2006; 16(6):281-7. PubMed ID: 17476973
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer.
Ramalingam SS; Harvey RD; Saba N; Owonikoko TK; Kauh J; Shin DM; Sun SY; Strychor S; Tighiouart M; Egorin MJ; Fu H; Khuri FR
Cancer; 2010 Aug; 116(16):3903-9. PubMed ID: 20564143
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer.
Ma CX; Suman VJ; Goetz M; Haluska P; Moynihan T; Nanda R; Olopade O; Pluard T; Guo Z; Chen HX; Erlichman C; Ellis MJ; Fleming GF
Breast Cancer Res Treat; 2013 May; 139(1):145-53. PubMed ID: 23605083
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies.
Spiridonidis CH; Laufman LR; Jones J; Rhodes VA; Wallace K; Nicol S
J Clin Oncol; 1998 Dec; 16(12):3866-73. PubMed ID: 9850032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
